How to Apply to Sarepta Therapeutics

11 min read Last updated April 20, 2026 19 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Sarepta is a focused rare disease biotech built around DMD, with Elevidys (AAV gene therapy, ~$3.2M per dose) now its primary growth driver alongside three approved exon-skipping PMOs.
  • Apply through Workday at sarepta.com/careers; structure your profile and resume to match Workday's parser and the specific modality and therapeutic area of the role.
  • Cambridge/Andover/Burlington MA roles skew toward R&D, clinical, regulatory, and commercial; Columbus OH is the center of gravity for AAV manufacturing and CMC.
  • Compensation is competitive with top Cambridge biotech: senior scientist roles commonly run $140-180K base plus bonus and equity, director-level $230-300K plus 25-35% target bonus and RSUs, with gene therapy manufacturing premium for specialized senior engineers.
  • Interviews are technically demanding and mission-forward; expect formal presentations for research roles and function-specific case work for regulatory, commercial, and CMC roles.
  • The DMD patient community, especially Parent Project Muscular Dystrophy (PPMD), is a real cultural presence; genuine engagement with that context is a durable differentiator.
  • Sarepta operates in a high-scrutiny regulatory environment — accelerated approval experience and intellectual honesty about data matter more here than at most biotechs.
  • Partnerships with Roche (ex-US Elevidys), Arrowhead (siRNA), and Genevant (LNP) mean roles increasingly span multiple modalities; breadth plus one deep specialty is a strong profile.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a US-based commercial-stage biotech headquartered in Cambridge, Massachusetts, focused on developing genetic medicines for rare diseases — most visibly Duchenne muscular dystrophy (DMD), a progressive, fatal pediatric muscle-wasting disease. Originally founded in 1980 as AntiVirals Inc., the company rebranded to Sarepta in 2011 and has since become one of the most closely watched names in rare disease drug development. As of 2024, Sarepta employs roughly 1,300 people and reported approximately $1.7 billion in revenue, a figure that has grown rapidly following the commercial ramp of its gene therapy Elevidys. The company is led by CEO Doug Ingram, who took the helm in 2017 and has been credited with transforming Sarepta from a single-drug antisense oligonucleotide (ASO) company into a multi-modality genetic medicine platform spanning ASOs, adeno-associated virus (AAV) gene therapy, siRNA, and novel chemistries. Sarepta's commercial portfolio reflects a decade of iterative innovation in DMD. EXONDYS 51 (eteplirsen) received FDA accelerated approval in 2016 for patients amenable to exon 51 skipping — a landmark decision that was internally contested at the agency and helped define the modern accelerated approval debate in neurology. VYONDYS 53 (golodirsen, 2019) and AMONDYS 45 (casimersen, 2021) followed, bringing exon 53 and 45 skipping therapies to market. In June 2023, the FDA granted accelerated approval to ELEVIDYS (delandistrogene moxeparvovec), an AAV gene therapy for DMD, and in June 2024 the label was expanded to a broader ambulatory and non-ambulatory population — one of the most consequential regulatory decisions in gene therapy to date. Elevidys is priced at roughly $3.2 million per dose, placing it among the most expensive drugs ever commercialized and making Sarepta one of the case studies other rare disease companies benchmark against. Beyond DMD, Sarepta is investing heavily in limb-girdle muscular dystrophies (LGMD), with multiple AAV gene therapy programs (SRP-9003, SRP-9004, and related constructs) across LGMD subtypes. A 2024 collaboration with Arrowhead Pharmaceuticals expanded the pipeline into siRNA, and partnerships with Genevant (lipid nanoparticle delivery) and Roche (ex-US Elevidys commercialization) round out a broader genetic medicines strategy. Main operating sites include the Cambridge, MA headquarters (R&D, commercial, G&A), an Andover, MA research center, a large gene therapy manufacturing campus in Columbus, Ohio (with legacy ties to Nationwide Children's Hospital), additional Burlington, MA footprint, and an Amsterdam, Netherlands office for European operations. If you are targeting Sarepta, it helps to think of it as a specialist rare disease company operating at the intersection of precision genetic medicine, complex manufacturing, and an unusually engaged patient community.

Application Process

  1. 1
    Find roles at sarepta

    Find roles at sarepta.com/careers, which routes to the company's Workday instance (myworkdayjobs.com/Sarepta). Create a Workday profile and expect to reuse it for any future applications.

  2. 2
    Filter by function (Research, Clinical Development, Regulatory, Manufacturing/CM

    Filter by function (Research, Clinical Development, Regulatory, Manufacturing/CMC, Commercial, G&A) and by primary location — most roles are Cambridge/Andover/Burlington MA or Columbus OH; some are remote or Amsterdam-based.

  3. 3
    Tailor your resume to the specific modality in the job description: AAV gene the

    Tailor your resume to the specific modality in the job description: AAV gene therapy, antisense oligonucleotides/PMO chemistry, siRNA, or LNP delivery. Generic 'biotech' framing underperforms here.

  4. 4
    Submit via Workday with a complete profile, uploaded resume, and a focused cover

    Submit via Workday with a complete profile, uploaded resume, and a focused cover letter that connects your experience to DMD, LGMD, rare disease, or viral vector work. Answer EEO, work authorization, and veteran status prompts accurately.

  5. 5
    Recruiter screen (30 minutes): expect questions on motivation for rare disease,

    Recruiter screen (30 minutes): expect questions on motivation for rare disease, familiarity with DMD or the relevant therapeutic area, comp expectations, location preference, and work authorization.

  6. 6
    Hiring manager interview: deeper dive on your technical background, recent proje

    Hiring manager interview: deeper dive on your technical background, recent projects, and how your skill set maps to the role's scope. Come prepared with one or two crisp project stories with measurable outcomes.

  7. 7
    Panel rounds (virtual or onsite): typically 4-6 interviewers across functional p

    Panel rounds (virtual or onsite): typically 4-6 interviewers across functional peers, cross-functional partners, and a skip-level leader. Research and medical roles usually require a formal 45-60 minute presentation or 'chalk talk' on prior work.

  8. 8
    Function-specific deep dives: regulatory candidates may get a regulatory case or

    Function-specific deep dives: regulatory candidates may get a regulatory case or mock FDA interaction; commercial candidates often present a mock launch or access strategy; CMC candidates may discuss a scale-up or deviation case study.

  9. 9
    References and background check: Sarepta typically requests 2-3 professional ref

    References and background check: Sarepta typically requests 2-3 professional references and runs standard background and education verification before offer.

  10. 10
    Offer and negotiation: total comp discussions include base, target bonus percent

    Offer and negotiation: total comp discussions include base, target bonus percentage, RSU grant, sign-on (often used for senior hires), and relocation where relevant. End-to-end timelines usually run 4-8 weeks; senior and specialized roles can run longer.

Resume Tips for Sarepta Therapeutics

recommended

Lead with modality-specific keywords in your summary and most recent role — 'AAV

Lead with modality-specific keywords in your summary and most recent role — 'AAV gene therapy,' 'antisense oligonucleotide (ASO),' 'PMO chemistry,' 'exon skipping,' 'siRNA,' 'LNP delivery,' or 'viral vector CMC' — matched to the job description.

recommended

Name therapeutic areas explicitly: Duchenne muscular dystrophy (DMD), limb-girdl

Name therapeutic areas explicitly: Duchenne muscular dystrophy (DMD), limb-girdle muscular dystrophy (LGMD), myology, neuromuscular disease, or rare/ultra-rare disease. Sarepta's Workday search and human reviewers both look for this alignment.

recommended

For research roles, list specific techniques: AAV capsid engineering, vector des

For research roles, list specific techniques: AAV capsid engineering, vector design, in vivo mouse models of muscular dystrophy (mdx, DBA/2J-mdx), biodistribution, immunogenicity assays, dystrophin quantification (Western, MS), and relevant cell or iPSC models.

recommended

For clinical development, highlight rare disease trial design, pediatric study e

For clinical development, highlight rare disease trial design, pediatric study experience, natural history data, functional endpoints (NSAA, 6MWT, timed function tests), and any interaction with DMD or neuromuscular patient populations.

recommended

For regulatory roles, call out FDA accelerated approval pathway work, confirmato

For regulatory roles, call out FDA accelerated approval pathway work, confirmatory trial strategy, BLA/sBLA submissions, advisory committee preparation, and experience with CBER or OTAT (now OTP). International experience with EMA, PMDA, or Health Canada is a plus.

recommended

For CMC/manufacturing, emphasize AAV process development, suspension or adherent

For CMC/manufacturing, emphasize AAV process development, suspension or adherent cell culture (HEK293, Sf9/baculovirus), downstream purification, analytical method development, tech transfer, and GMP scale-up for viral vectors. Columbus roles weight this heavily.

recommended

For commercial and market access, highlight rare disease launch experience (Sare

For commercial and market access, highlight rare disease launch experience (Sarepta, BioMarin, Alexion, Ultragenyx, Vertex CF, Horizon/Amgen rare), payer strategy for high-cost one-time therapies, patient services design, and field force build-out.

recommended

Quantify impact: patients treated, INDs/BLAs filed, sites activated, capsids scr

Quantify impact: patients treated, INDs/BLAs filed, sites activated, capsids screened, titer improvements, yield gains, launch metrics, or access wins. Avoid task-list bullets without outcomes.

recommended

Mirror Sarepta's public language on mission and patients

Mirror Sarepta's public language on mission and patients. The careers site and leadership talks consistently center DMD families; showing awareness of that context signals cultural fit without being performative.

recommended

Keep it to 1-2 pages, ATS-clean (no columns, text boxes, or images), and submit

Keep it to 1-2 pages, ATS-clean (no columns, text boxes, or images), and submit as a PDF. Reserve a longer publications/patents list for an appendix or link to an ORCID/Google Scholar profile.

ATS System: Workday

Sarepta uses Workday for job postings and applications, hosted at sarepta.wd1.myworkdayjobs.com with the consumer-facing entry point at sarepta.com/careers. Workday parses uploaded resumes into structured fields (experience, education, skills) and ranks candidates against job requisition keywords. Recruiters and hiring managers see the parsed profile first, so resume structure directly affects how your background is represented.

  • Upload a clean PDF and then review every auto-parsed field in the Workday profile — fix any mis-parsed job titles, dates, or education entries before submitting.
  • Use standard section headings (Experience, Education, Skills, Publications) so Workday's parser maps them correctly; avoid creative headers or two-column layouts.
  • Mirror exact phrases from the job description for modality, therapeutic area, and technique — 'Duchenne muscular dystrophy,' 'AAV9,' 'process development,' 'medical affairs,' and so on.
  • Fill in the optional Skills section in Workday with the same keyword set; this is searchable separately from the resume.
  • Answer all screening questions (work authorization, sponsorship, location, salary expectations) accurately — Workday uses these as hard filters.
  • Set up job alerts in Workday for saved searches; Sarepta posts in waves, and early applications are reviewed first.
  • If you are applying for multiple roles, tailor each submission rather than reusing one generic application; Workday preserves distinct resumes per requisition.
  • Keep your Workday profile updated even when you are not actively applying — recruiters source from existing profiles for new requisitions.

Interview Culture

Interviewing at Sarepta tends to feel more mission-forward than a typical large pharma process.

Expect early and direct questions about why you want to work on DMD or rare disease specifically, and about your comfort with the emotional weight of serving a pediatric, progressive patient population. Families from the DMD community — often connected through Parent Project Muscular Dystrophy (PPMD) — are a visible presence at company events, and that context shapes how interviewers frame the work. On the technical side, the bar is high and specialized. Research and preclinical candidates usually give a 45-60 minute presentation on prior work, followed by a chalk-talk style discussion of how they would approach a hypothetical problem relevant to the team. Clinical development interviews dig into trial design choices, endpoint selection, and interpretation of functional data in small populations. Regulatory interviews often include a case on accelerated approval strategy, confirmatory trial design, or FDA interaction planning — areas where Sarepta has uniquely deep institutional experience. CMC interviews for Columbus-based roles probe AAV process details: cell line selection, upstream productivity, downstream purification, analytical comparability, and tech transfer. Commercial and medical affairs interviews tend to be case-heavy, reflecting the complexity of launching and expanding $3M+ one-time therapies. Expect scenarios involving payer pushback, patient identification, hub services, and managing the distinct dynamics of a physician community that is small, highly connected, and deeply invested in outcomes. Across functions, interviewers reliably assess three things: depth in your domain, ability to operate in ambiguity, and genuine engagement with the patient mission. Candidates who treat rare disease as a generic biotech play — or who overclaim — tend to surface quickly.

What Sarepta Therapeutics Looks For

  • Authentic connection to rare disease, neuromuscular disorders, or pediatric patient populations — not just a willingness to learn, but evidence you have already chosen this space.
  • Deep modality expertise in at least one of Sarepta's core platforms: AAV gene therapy, antisense oligonucleotides (PMO), siRNA, or LNP delivery, with specific technical accomplishments to back it up.
  • Comfort operating under FDA accelerated approval frameworks, including awareness of confirmatory trial obligations, post-marketing commitments, and the regulatory scrutiny that comes with them.
  • Scientific rigor and intellectual honesty — the DMD community and Sarepta's own history reward candidates who acknowledge uncertainty and data limitations rather than oversell.
  • Execution at pace: Sarepta runs several programs in parallel across modalities and indications, so hiring managers look for people who can ship in ambiguous, fast-moving environments.
  • Cross-functional fluency, especially between R&D, CMC, regulatory, and commercial; the company's structure rewards people who can translate across these boundaries.
  • For manufacturing and CMC, hands-on viral vector experience at scale — AAV is technically unforgiving, and Sarepta's Columbus operation is a major strategic asset.
  • For commercial roles, a track record in rare disease launches or access for high-cost therapies, plus genuine comfort with small-market, high-touch field models.
  • Cultural alignment with a mission-driven, patient-centered organization — measured less by slogans and more by concrete past choices.
  • Coachability and collaboration: interview panels consistently flag candidates who are brilliant individually but difficult to partner with.

Frequently Asked Questions

What does compensation typically look like at Sarepta Therapeutics?
Sarepta pays at the top end of the Cambridge biotech market, though exact numbers vary by role, level, and location. Public ranges and aggregators suggest senior scientist roles commonly land around $140-180K base plus bonus and RSUs, director-level positions around $230-300K base with 25-35% target bonus and meaningful equity, and senior process engineering or gene therapy manufacturing roles at a premium — often $150-200K+ for experienced candidates. Executive retention packages have been notable given Elevidys' commercial success. Treat any specific figure as directional and verify against the offer letter and your own negotiation; compensation specifics are not publicly disclosed in detail.
How should I choose between Cambridge-area roles and Columbus roles?
It mostly tracks function. Cambridge, Andover, and Burlington host R&D, clinical development, regulatory, medical affairs, commercial, and most G&A roles, so if you are in discovery research, translational science, or headquarters functions, Massachusetts is where the critical mass lives. Columbus, Ohio is Sarepta's gene therapy manufacturing hub, built around AAV process development, GMP production, and quality. If your expertise is in viral vector CMC, process engineering, analytical development, or manufacturing science, Columbus is often the better center of gravity. Some roles are hybrid or remote; location requirements are listed on each Workday posting.
Is gene therapy manufacturing a good career path to target at Sarepta?
Yes, and it is one of the more durable bets in the industry right now. AAV manufacturing is technically demanding, capacity is constrained across the sector, and Sarepta's Columbus operation is a strategic asset supporting Elevidys and multiple LGMD programs. Roles in process development, cell culture, downstream purification, analytical method development, tech transfer, MSAT, and quality are all relevant. Candidates with hands-on viral vector experience — particularly at scale and under GMP — are in high demand across biotech, and Sarepta has the program density to offer long-term growth.
Does Sarepta sponsor work visas?
Sarepta sponsors work visas for specialized roles where the skill set is scarce, which is common in AAV research, CMC, and certain clinical and regulatory positions. Sponsorship is not guaranteed for every role; the Workday application asks directly whether you require current or future sponsorship, and that answer is treated as a hard input. If sponsorship is important, target roles where your technical specialization is clearly differentiated, and address it transparently during the recruiter screen.
How central is the DMD patient community to daily life at Sarepta?
More than at most biotechs. Parent Project Muscular Dystrophy (PPMD) and individual DMD families are visible at company events, in patient advisory work, and in how programs are prioritized. Leadership regularly references the patient community in internal communications and external talks. For candidates, this means two things: first, your interest in the mission will be probed directly in interviews, and second, the emotional stakes of the work — especially in pediatric trials and gene therapy — are real and ongoing. Candidates who thrive here tend to see that as part of the job, not a distraction from it.
How has the June 2024 Elevidys label expansion affected hiring?
The 2024 expansion of the Elevidys label to a broader ambulatory and non-ambulatory DMD population meaningfully grew the eligible patient pool and, by extension, the commercial, medical affairs, patient services, market access, and manufacturing support needs around the product. That has translated into sustained hiring in commercial field roles, payer and access functions, patient hub operations, and manufacturing scale-up. R&D hiring continues to be driven by the LGMD pipeline and next-generation platform work rather than Elevidys directly.
How does the Roche partnership affect career opportunities at Sarepta?
Roche is Sarepta's ex-US commercialization partner for Elevidys, which means outside the United States, Roche generally leads commercial execution while Sarepta retains US commercial rights and global development responsibilities. Practically, this shapes where you will find Sarepta commercial roles (heavily US-weighted) versus where you will see Roche-led field activity (ex-US). Sarepta's Amsterdam office supports European development, medical, and regulatory work, and alliance management with Roche is itself a meaningful function at Sarepta.
What should I understand about Sarepta's regulatory history before interviewing?
Sarepta's relationship with the FDA is unusual and worth studying. The 2016 accelerated approval of EXONDYS 51 was internally contested at the agency and helped shape the modern accelerated approval debate in neurology. Elevidys' 2023 accelerated approval and 2024 label expansion were similarly high-profile decisions. Candidates in regulatory, clinical development, and senior R&D roles should be able to discuss accelerated approval, confirmatory trial design, post-marketing commitments, and advisory committee dynamics without overclaiming or dismissing legitimate scientific debate. Intellectual honesty on this history tends to land well with interviewers.
How does Sarepta's culture compare to other rare disease biotechs like BioMarin or Ultragenyx?
All three companies share a rare disease ethos, but they feel different day to day. Sarepta is more narrowly focused — DMD and neuromuscular are central in a way few other companies match — and the combination of a single dominant patient community and high-profile regulatory history makes the environment particularly mission-forward and, at times, intense. BioMarin is broader across rare indications and has a more established operational footprint. Ultragenyx is smaller and more heterogeneous in its pipeline. Culture fit often comes down to whether you want depth in one community (Sarepta) versus breadth across many (BioMarin, Ultragenyx).
How should I think about Sarepta's antisense versus AAV gene therapy programs when choosing a role?
Both matter, but they are at different points in their lifecycles. The antisense/PMO franchise (EXONDYS 51, VYONDYS 53, AMONDYS 45) is commercial, mature, and generates steady revenue and lifecycle management work. The AAV gene therapy platform, anchored by Elevidys and extending into multiple LGMD programs, is the primary growth engine and where much of the current R&D, CMC, and commercial investment is directed. If you want commercial stability and optimization work, antisense-adjacent roles fit; if you want to be close to the frontier of pediatric gene therapy and rare disease platform expansion, AAV-side roles are the clearer bet.
Has Sarepta experienced significant executive turnover, and should that influence how I evaluate the company?
Sarepta has had notable executive movement over the years, which is not unusual for a company of its size operating through multiple launches, regulatory cycles, and partnership structures. Doug Ingram has been CEO since 2017 and has provided continuity at the top. When evaluating a specific role, look at the tenure of the hiring manager and their skip-level, ask directly in interviews about team stability, and read recent 10-K and proxy disclosures for named executive officer changes. Endpoints News, STAT, and FiercePharma regularly cover leadership transitions in the sector and are useful background reading.

Open Positions

Sarepta Therapeutics currently has 19 open positions.

Check Your Resume Before Applying → View 19 open positions at Sarepta Therapeutics

Related Resources

Similar Companies

Related Articles

Sources

  1. Sarepta Therapeutics — Careers —
  2. Sarepta Therapeutics — About Us —
  3. Sarepta Therapeutics — Pipeline —
  4. Sarepta Therapeutics — Annual Report and SEC 10-K Filings —
  5. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy (Elevidys, June 2023) —
  6. FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy (Elevidys Label Expansion, June 2024) —
  7. Sarepta Therapeutics and Roche Announce Elevidys Ex-US Collaboration —
  8. Sarepta Therapeutics and Arrowhead Pharmaceuticals Announce siRNA Collaboration (2024) —
  9. Endpoints News — Sarepta Therapeutics Coverage —
  10. STAT News — Sarepta and Duchenne Muscular Dystrophy Reporting —
  11. Parent Project Muscular Dystrophy (PPMD) —
  12. Sarepta Therapeutics on LinkedIn —
  13. Sarepta Therapeutics on Glassdoor —
  14. FDA Peripheral and Central Nervous System Drugs Advisory Committee — Elevidys Briefing Documents —
  15. Sarepta Therapeutics Workday Careers Portal —